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Xiaowen Liu1,2, Hongmei Yu1,2, Hong Cai1,2 and Yanong Wang1,2*Abstract
Background and objective: miR-132 plays a role in regulating neuronal morphology and cellular excitability. Little
is known about the effects of miR-132 in cancer. The aim of this study is to evaluate the expression of miR-132 and
its clinical significance in gastric cancer.
Methods: Cancerous tissues and corresponding normal tissues from 79 patients with gastric cancer were examined
for the expression of miR-132 using quantitative PCR and the association between miR-132 expression levels and
clinicopathological factors and prognosis was analyzed.
Results: In 79 clinical samples of gastric cancer patients, miR-132 expression levels in cancer tissues were significantly
higher than those in the corresponding normal tissues (P = 0.001). Higher expression levels of miR-132 were associated
with more frequent lymph node metastasis (P = 0.033), more lymphatic tumor emboli (P = 0.007), and more advanced
stage (P = 0.016). Additionally, expression of miR-132 was an independent prognostic factor for overall survival
(P = 0.020).
Conclusion: miR-132 could serve as an efficient prognostic factor for gastric cancer patients.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/8168577241196050
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Although the incidence of gastric cancer has been substan-
tially declining for several decades, it is still the fourth most
common cancer and the second most frequent cause of
cancer death [1,2]. A multiple of genes seem to contribute
to the malignant biological behaviour of gastric cancer
[3,4]. It is very important to identify the prognostic factors
in order to maximize the therapeutic effect and to minimize
the adverse effects in the treatment of cancer patients.
MicroRNAs are a class of endogenous small noncod-
ing RNAs that function as gene regulators by regulating
messenger RNA translation and degradation [5]. Micro-
RNAs play a crucial role in regulating the normal func-
tions such as proliferation, differentiation, and apoptosis.
Moreover, dysregulation of miRNAs contribute to the* Correspondence: wangyn1111@hotmail.com
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unless otherwise stated.carcinogenesis and cancer progression [6,7]. As a mem-
ber of miRNAs family, miR-132 plays an important role
in inflammation, angiogenesis, and neural development
[8-10]. Recently, some studies showed that the dysre-
gulation of miR-132 was related to a variety of human
tumors, such as non-small cell lung cancer, osteosarcoma,
breast cancer, hepatocellular carcinoma, prostate cancer,
and pancreatic cancer [11-16]. However, there are no
reports about the expression and clinical significance of
miR-132 in gastric cancer.
In this study, the miR-132 expression in gastric cancer
patients was examined and the association between
miR-132 and clinicopathological parameters was analyzed.
Additionally, we evaluated the expression of some pro-
teins involved in cell-cycle control (p21, p53), tissue prolif-
eration and differentiation (c-myc). p21 and p53 proteins
are the products of tumor-suppressor genes, which are
activated by modulating cell proliferation via control of
the G1 arrest checkpoint of the cell cycle [17,18]. c-myc
protein is a type of transcription factor.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Human gastric cancer and corresponding normal tissues
were obtained from 79 patients who underwent gas-
trectomy at the Department of Gastric Cancer and Soft
Tissue Sarcomas, Fudan University Shanghai Cancer
Center, between January 2007 and December 2009. Par-
tial gastrectomy was performed in 36 patients, and total
gastrectomy was performed in the other 43 patients. At
least 4 cm resection margins from gross tumor were
guaranteed for all patients. A total of 71 patients received
adjuvant chemotherapy. After resection, the specimens
were immediately frozen in liquid nitrogen and then
stored in −80° refrigerator. Inclusion criteria for this study
were adenocarcinoma and complete pathological data;
Exclusion criteria were neoadjuvant therapy, peritoneal
dissemination, and distant metastasis. Data were retrieved
from their operative and pathological reports, and follow-
up data were obtained by phone outpatient and clinical
database. The written informed consent had been ob-
tained from all the patients, and this study was approved
by the Ethical Committee of Shanghai Cancer Center of
Fudan University.
RNA extraction and quantitative real-time PCR
The total RNA from tissue was extracted with TRIzol
reagent (Invitrogen, Carlsbad, CA, USA) following the
manufacturer’s instructions. Quantitative real-time PCR
(qRT-PCR) assays were carried out to detect the endo-
genous expression of miR-132 according to the Applied
Biosystems method. Briefly, cDNA was reverse transcribed
from total RNA samples using a miRNA-specific stem-
loop primer from the Taqman MicroRNA Assays and
reagents from the TaqMan® MicroRNA Reverse Transcrip-
tion Kit (ABI, Forest City, CA, USA). Then, PCR products
were amplified from cDNA samples using the TaqMan
MicroRNA Assays together with the TaqMan® Universal
PCR Master Mix and the amount of PCR product were
monitored using Applied Biosystems 7900 Sequence
Detection System. U6 small nuclear RNA was used as
an internal control. The relative amount of miR-132 was
calculated by using 2(−Delta DeltaC(T)) method [19].
Immunohistochemical staining
p21, p53, and c-myc were detected by immunohistochem-
ical method. All primary antibodies and mouse monoclo-
nal antibodies were purchased from Dako (Hamburg.
Germany). Immunohistochemical staining was performed
by the enhance labeled polymer system (ELPS) method.
After overnight incubation at 4°C with anti-p21, p53, and
c-myc antibody, sections were treated according to stand-
ard immunoperoxidase methods using a streptavidin bio-
tin peroxidise complex kit (LSAB +Kit/HRP; Dako). The
peroxidise reaction was then developed with diaminoben-
zidine (Dako). Negative control sections were subjected tothe same procedure except that the first antibody was
replaced by phosphate buffer saline (PBS) [20].
Immunohistochemical staining scoring
All the slices were evaluated by two pathologists without
knowledge of clinical outcome. The percentage of immu-
noreactive cells and staining intensities were evaluated in
each sample. The percentage of immunoreactive cells was
graded on a scale of 0 to 4: no staining is scored as 0,
1-10% of cells stained scored as 1, 11-50% as 2, 51-80% as
3, and 81-100% as 4. The staining intensities were graded
from 0 to 3: 0 is defined as negative, 1 as weak, 2 as mod-
erated, and 3 as strong, respectively. The raw data were
converted to the immunohistochemical score (IHS) by
multiplying the quantity and intensity scores. On the final
analysis, the cases had a score of less than 1 were consid-
ered as negative, and ≥ 1 was regarded as positive [20].
Statistical analysis
The patients’ features and clinicopathological characteris-
tics were analyzed using the two-tailed Student’s t-test for
continuous variable and χ2 test for categorical variable.
Overall survival curves were calculated by Kaplan-Meier
method, and the differences between survival curves were
examined with long-rank test. The independent prognos-
tic factors were examined by the multivariate survival ana-
lysis using Cox proportional hazards model. The accepted
level of significance was P <0.05. Statistical analyses and
graphics were performed using the SPSS 13.0 statistical
package (SPSS, Inc., Chicago, IL).
Results
Clinicopathological characteristics
There were 62 males and 17 females (3.6:1) with a mean
age of 58 years. There was 7 (8.9%) early gastric cancers
and 72 (91.1%) advanced gastric cancers. According to
histological type, well-differentiated tumors were observed
in 3 (3.8%) patients, moderately-differentiated in 11 (13.9%)
patients, and poorly-differentiated tumors in remaining 65
(82.3%) patients. Of 79 patients, 25 (31.6%) had tumors
located in the upper third, 15 (19.0%) had tumors in the
middle third, 36 (45.6%) had tumors in the lower third of
the stomach, and 3 (3.8%) had tumors occupied two-thirds
or more of stomach. Lymph node metastasis was observed
in 57 patients, the metastasis rate was 72.2%. The distri-
bution of pathological stage was as follows: 10 (12.6%) pa-
tients belonged to stage I, 24 (30.4%) II, and 45 (57%) III.
The expression and correlation of miR-132, p21, p53, and
c-myc
miR-132 levels in 79 cancerous (T) and corresponding
normal tissues (N) were examined by qRT-PCR. Most
tumor tissues (57/79, 72%) showed elevated levels of miR-
132 compared to the corresponding normal tissues, with a
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tissues (mean ± SD, 0.35 ± 0.58) were significantly higher
than those in the corresponding noncancerous tissues
(mean ± SD, 0.15 ± 0.35, P < 0.05). The expressions of
p21, p53, and c-myc were examined by immunohisto-
chemical staining. p21 expression was positive in 64.6% of
all gastric cancer tissues. p21 staining was observed in the
nucleus of carcinoma cells. p53 expression was positive in
74.7% of all gastric cancer tissues. p53 staining was ob-
served in the nucleus of carcinoma cells. c-myc expression
was positive in 44.3% of all gastric cancer tissues. c-myc
staining was observed in the cytoplasm of carcinoma cells.
miR-132 expression was associated with p53 and c-myc.
There was no correlation with p21. Additionally, p53ex-
pression was associated with c-myc (Table 1).
Clinical significance of miR-132 in gastric cancer
79 gastric cancer patients were divided into two groups
including miR-21 high-expression group (T/N >0.5, n = 33)
and low-expression group (T/N <0.5, n = 46) according to
the median T/N ration of miR-132 expression. The correl-
ation between miR-132 expression and pathological para-
meters was analyzed. The results showed that patients with
high miR-132 expression had more frequent lymph node
metastasis (P = 0.033), more lymphatic tumor emboli
(P = 0.007), and more advanced stage (P = 0.016). However,
there were no significant differences about gender, age,
histological type, tumor location, tumor size, nervous
invasion, and T stage (Table 2). In the overall survival, the
patients with the miR-132 high expression had a sig-
nificantly poorer prognosis than those with miR-132 low
expression (P = 0.000) (Figure 1). Univariate analysis of
overall survival showed that the relative expression of
miR-132, nervous invasion, lymphatic tumor emboli, and
pathological stage were prognostic predictors. Multivariate
survival analysis, including all significant prognostic fac-
tors mentioned in univariate analysis, was performed to
determine the independent prognostic factors for gastric
cancer. Multivariate analysis showed that the miR-132 ex-
pression level and pathological stage were independent
prognostic factors (Table 3).
Discussion
The identification of prognostic factors in gastric cancer
was essential for predicting patients’ survival and determin-
ing optimal therapeutic strategies. The depth of invasionTable 1 Positive results of correlations among biological
markers
Biological markers Correlation coefficients (r) P value
miR-132 P53 0.274 0.015
miR-132 c-myc 0.228 0.044
P53 c-myc 0.235 0.038and lymph node metastasis were the most important prog-
nostic factors in gastric cancer. As a result of the variability
of prognosis within same pathological stage of gastric
cancer, there have been a lot of researches for specific
biological markers to identify patients with prognosis
[21-28]. The biological markers such as microRNA, c-Met,
L1CAM, endothelial lipase protein, variable copy number
of mitochondrial DNA (mtDNA), TIMP3, hK6, and Ezrin
have been studied extensively. As a novel biomarker, the
potential of miRNAs in predicting prognosis is increasingly
Figure 1 Comparison of survival according to the expression of
miR-132. There were significant differences between miR-132 high
expression and miR-132 low expression (P = 0.000).
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from an intergenic region on human chromosome 17 by
the transcription factor cAMP response element binding
protein [29]. Most of the reports bout miR-132 regulation
and biological functions emerged from the studies per-
formed in the neuronal context. Additionally, miR-132 has
also been described in a number of other fields, such as in-
flammation, cell transformation and tumourigenesis. miR-
132 was shown to be up-regulated or down-regulated
in different human cancers [16,30,31]. Some studies
showed that miR-132 could promote cell proliferation
[31]. However, there are still no reports on miR-132 in
gastric cancer.
In this study, we investigated miR-132 expression in
gastric cancer and determined if it could predict patient
outcomes. We found that miR-132 expression was higher
in cancerous tissues compared with corresponding normal
tissues. The exact cause of the miR-132 high expression in
gastric cancer is unknown. Park JK et al. reported [31] that
the B2AR agonist terbutaline increases miR-132 expres-
sion. miR-132 was transcriptionally activated by CREB in
neurons [32]. B2AR antagonists inhibited activation of
CREB [33]. Therefore, it is possible that simulation ofTable 3 Multivariate analysis of patients by Cox model
Variable χ2 P vale RR 95% CI
miR-132 expression 5.447 0.020 2.414 1.152-5.059
Nervous invasion 1.918 0.166 1.890 0.768-4.655
Lymphatic tumor emboli 0.173 0.677 0.838 0.366-1.923
Pathological stage 8.742 0.003 4.356 1.642-11.555B2AR increase miR-132 expression following activa-
tion of CREB.
The results showed that high miR-132 expression in
gastric cancer was significantly correlated with aggres-
sive clinicopathological characteristics such as more
frequent lymph node metastasis, more lymphatic tumor
emboli, and more advanced stage. These results sug-
gested that upregulation of miR-132 played an important
role in gastric cancer progression. Interestingly, we
found that miR-132 expression was associated with p53
and c-myc. Some previous studies showed that some
microRNAs could mediate and regulate tumor suppres-
sion exerted by p53 or c-myc [34,35]. Jiang L et al. [34]
found that has-miR-125a-3p could induce apoptosis via
the p53 pathway. Zhang N, et al. [35] found that miR-
150 could promote the proliferation of lung cancer cells
by targeting p53. Wang B et al. [36] found that there
was a double negative feedback loop between miR-122
and c-myc in hepatocellular cancer. Li X, et al. [37]
found that c-MYC promoted the expression of mature
miR-23a, miR24-2, and miR27a and subsequently pro-
moted mammary carcinoma cell migration and invasion.
However, the exact correlation between miR-132 and
p53, c-myc is unclear and remains to be elucidated in
future studies. We investigated the correlation of miR-
132 expression with prognosis of gastric cancer patients,
found that patients with high miR-132 expression had
poorer overall survival that those with low miR-132
expression. More importantly, multivariate analysis
revealed that high miR-132 expression was independent
prognostic indicator. It was controversy whether miR-
132 played same prognostic value in different kinds of
tumors. Parker et al. reported [38] that high expression
of miR-132 was associated with poor prognosis in pa-
tients with primary glioblastoma multiforme. However,
Yang et al. [12] reported that osteosarcoma patients with
low miR-132 expression had poorer overall and disease-
free survival. It was possible that miR-132 played differ-
ent functions in different tumors. Wang et al. [39] found
that overexpression of miR-132 suppressed in vitro cell
proliferation and in vivo tumor growth. Li et al. [13]
showed that overexpression of miR-132 could inhibit the
proliferation of breast cancer cell. Conversely, Park et al.
[31] reported that over-expression of miR-132 increased
the pancreatic cancer cell proliferation.
Taken together, our study indicated that miR-132 was
upregulated in gastric cancer and might be an independ-
ent molecular biomarker for predicting the prognosis of
gastric cancer. Meanwhile, as a result of small sample re-
search, a large case research is needed to confirm the
prognostic value of miR-132 in gastric cancer.Competing interests
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